ArticleScientific reports2021
Comparative assessment of antimicrobial, antiradical and cytotoxic activities of cannabidiol and its propyl analogue cannabidivarin.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A Comparative Analysis of the Action Mechanisms of Cannabidiol, Cannabigerol, and Cannabinol in Human Cholangiocarcinoma Cell Lines.Molecules (Basel, Switzerland) · 2026Article
- MCPB-21 targets glycogenin-2 to regulate fatty acid oxidation and promote ferroptosis of breast cancer.American journal of cancer research · 2026Article
- Potential Antimicrobial Use of Cannabidiol in Dentistry: A Scoping Review.Dentistry journal · 2025Review
- Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.Microorganisms · 2025Review
- Correlation between Chemical Fertilization Practices, Phytochemical Response, and Biological Activities ofCombinatorial chemistry & high throughput screening · 2025Review
- Cannabidivarin and cannabigerol induce unfolded protein response and angiogenesis dysregulation in placental trophoblast HTR-8/SVneo cells.Archives of toxicology · 2024Article
- Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids.Antibiotics (Basel, Switzerland) · 2024Article
- Opportunities, Challenges, and Scientific Progress in Hemp Crops.Molecules (Basel, Switzerland) · 2024Review
- A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders.Journal of cannabis research · 2024Review
- Cannabidiol-loaded microparticles embedded in a porous hydrogel matrix for biomedical applications.Journal of materials science. Materials in medicine · 2024Article
- Cannabis sativa L.: A comprehensive review on legislation, decriminalization, phytochemistry, antimicrobial activity, and safety.Journal of food and drug analysis · 2023Review
- Cannabidiol-Loaded Nanoparticles Based on Crosslinked Starch: Anti-Inflammatory Activity and Improved Nose-to-Brain Delivery.Pharmaceutics · 2023Article
- Biosynthesis of Phytocannabinoids and Structural Insights: A Review.Metabolites · 2023Review
- The dual role of cannabidiol on monocyte-derived dendritic cell differentiation and maturation.Frontiers in immunology · 2023Article
- Evaluation ofMetabolites · 2022Article
- Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain.Biomolecules · 2022Article
- Extraction, Physicochemical Properties, Anti-Aging, and Antioxidant Activities of Polysaccharides from Industrial Hemp Residues.Molecules (Basel, Switzerland) · 2022Article
- The Antimicrobial Properties of Cannabis and Cannabis-Derived Compounds and Relevance to CB2-Targeted Neurodegenerative Therapeutics.Biomedicines · 2022Review
- Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research.Biomolecules · 2022Review
- Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol and cannabidivarin are phytocannabinoids produced by Cannabis indica and Cannabis sativa. Cannabidiol has been studied more extensively than its propyl analogue cannabidivarin. Therefore, we performed a battery of in vitro biological assays to compare the cytotoxic, antiradical and antibacterial activities of both cannabinoids. Potential mitochondrial metabolism alterations, DNA synthesis inhibition, and plasma membrane damage were studied by MTT assay, BrdU-ELISA and LDH assay of cancer and normal human cells exposed to cannabinoids. ABTS and DPPH assays were performed to observe the effects of the cannabinoids on free radicals. Microbial susceptibility tests were performed to study the activity of the cannabinoids in two bacterial species implicated in human infections, Escherichia coli and Staphylococcus aureus. The results showed that the cannabinoids induced medium levels of cytotoxicity in cancer and normal cells at concentrations ranging from 15.80 to 48.63 and from 31.89 to 151.70 µM, respectively, after 72 h of exposure. Cannabinoids did not exhibit a strong antioxidant capacity in scavenging ABTS or DPPH radicals. No evident differences were observed between the two cannabinoids in antimicrobial activity, except with respect to S. aureus, which showed greater susceptibility to cannabidiol than to cannabidivarin after 72 h of exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.